SOMATULINE Clinical, Regulatory & Commercial Intelligence Report 2026-2034 | Clinical Evidence Supports Long-Term Use
A market intelligence report on SOMATULINE (lanreotide) projects continued growth through 2034 across seven major markets despite generic competition. The long-acting somatostatin analog maintains strong clinical evidence and physician confidence for treating acromegaly, neuroendocrine tumors, and carcinoid syndrome. Ipsen reported 4.3% sales growth in fiscal 2025, with expectations for continued expansion supported by improved diagnosis rates and convenient prefilled syringe administration.